Status and phase
Conditions
Treatments
About
The safety and immunogenicity of AdCLD-CoV19-1 OMI (5.0x10^10 VP (0.5 mL)/dose/Vial) administered as a booster in healthy adults aged 19 years old and above will be evaluated.
Enrollment
Sex
Ages
Volunteers
Inclusion criteria
(Part A) Individual aged between 19-64 years old and willing to provide written informed consent to participate study voluntarily.
(Part B) Individual aged 19 years and above and willing to provide written informed consent to participate study voluntarily.
Individual fall under one or more of the following;
Individual with body mass index (BMI) of 30.0 kg/m2 or less at screening visit.
Individual who agrees with using an effective birth control method for at least 4 weeks before the screening and during the study period.
Individual who agrees not to donate or transfuse blood (including whole blood, plasma components, platelet components, and platelet plasma components) during the study period.
Exclusion criteria
Individual who has history of COVID-19 or is considered infected within 16 weeks (112 days) prior to administration of investigational product.
Individual who has received other COVID-19 vaccine within 16 weeks (112 days) prior to administration of investigational product.
Individual who has been in close contact with a COVID-19 infected person, or has been classified as a confirmed or suspected COVID-19 patient within 14 days prior to administration of investigational product.
Individual determined to be clinically significantly abnormal by the screening outcome based on laboratory evaluations, electrocardiogram (ECG) and Chest X-ray.
Individual who has ant results of positive to HIV test, hepatitis B test, and hepatitis C test on screening.
Acute febrile illness with 38°C and above, or any suspected infectious diseases, or symptoms similar to COVID-19 (cough, shortness of breathe, chills, myalgia, headache, sore throat, loss of taste/smell, etc.) within 3 days prior to administration of investigational product.
Any serious medical or psychiatric disease which in opinion of investigator judges unable to participate
History of splenectomy.
History of SARS-CoV or MERS-CoV infection.
Known history of allergic or hypersensitivity to the components of investigational product.
Known history of serious adverse reactions, allergies or hypersensitivity related to vaccination.
History of urticaria within 5 years prior to administration of investigational product.
Individual with history of bleeding diathesis or thrombocytopenia, or history of severe bleeding or bruising after intramuscular or intravenous injection, or is receiving an anticoagulant (Those who receive low dose aspirin (less than 100mg/day) are not excluded).
Individual with hereditary or idiopathic angioneurotic edema.
Individual with solid organ or bone marrow transplantation.
Individual who is suspected or with history of substance abuse and alcohol abuse within 24 weeks prior to administration of investigational product.
History of SARS-CoV or MERS-CoV vaccination.
History of licensed drug for COVID-19 treatment or prevention aside from COVID-19 vaccine within 52 weeks prior to administration of investigational product.
Use of immunosuppressive or chronic use of systemic steroids within 6 weeks prior to administration of investigational product (External steroids, nasal spray and inhalants are allowed).
Individuals who has administered other investigational product or device within 24 weeks prior to screening visit.
Individual concomitantly enrolled or scheduled to be enrolled in another trial (including follow-up period).
Individual vaccinated or planned vaccination within 28 days prior and after the administration of investigational product.
Receipt of immunoglobulin or blood-derived products within 12 weeks prior to administration of investigational product.
Individual with scheduled surgery during the study period.
Pregnant or lactating women.
Individual directly related to the investigator and meets the following conditions:
Individual who is unfit for this study for any other reason in judgement of investigator.
Primary purpose
Allocation
Interventional model
Masking
320 participants in 3 patient groups, including a placebo group
Loading...
Data sourced from clinicaltrials.gov
Clinical trials
Research sites
Resources
Legal